Quantcast

Latest Clopidogrel Stories

2014-06-19 10:12:13

Washington University in St. Louis Researchers have identified the first genetic variations linked to race that begin to explain a higher risk of death among some African American and Caucasian patients taking the anti-clotting drug clopidogrel (Plavix) after a heart attack. These variants increased patients’ risk of dying in the year following a first heart attack, but they appeared to do so for different reasons depending on race, according to a study at Washington University...

2014-05-21 12:26:28

Branded Products That Improve Hospital-Based Outcomes Have Advantages in Securing Preferred Drug Status in ACOs, According to Findings from Decision Resources Group BURLINGTON, Mass., May 21, 2014 /PRNewswire/ -- Decision Resources Group finds that managed care organizations and cardiologists alike believe accountable care organizations (ACOs) will reduce costs and improve outcomes for acute coronary syndrome (ACS) and atrial fibrillation (AF). A survey of 100 non-interventional cardiologists...

2014-05-06 16:32:03

OTTAWA, May 6, 2014 /CNW/ - Health Canada today released the April 2014 issue of the Canadian Adverse Reaction Newsletter (CARN). This issue features an article on the risk of a potentially life-threatening condition called drug reaction with eosinophilia and systemic symptoms suspected of being associated with azithromycin, an antibiotic used to treat a variety of infections. It also includes an article on quetiapine, a drug used to treat certain psychiatric disorders, and...

2014-04-02 08:32:38

BRANFORD, Conn., April 2, 2014 /PRNewswire/ -- New Haven Pharmaceuticals, Inc. (the "Company"), a privately held specialty pharmaceuticals company, today announced the appointment of Larry Dillaha, M.D., to the newly-created position of Executive Vice President Operations. Dr. Dillaha joins the Company from Insys Therapeutics, Inc. (Nasdaq: INSY) where he served as Chief Medical Officer since April 2010. "We are delighted to welcome Larry, who will provide significant insight and...

2014-03-21 16:23:29

NEW YORK, March 21, 2014 /PRNewswire/ -- Pomerantz LLP has filed a class action lawsuit against The Medicines Company ("Medicines" or the "Company") (NASDAQ: MDCO) and certain of its officers. The class action, filed in United States District Court, District of New Jersey, and docketed under 2:33-av-00001, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Medicines securities between February 20, 2013 and February 12, 2014 both dates...

2014-03-18 23:33:25

Rapid CYP2C19 Testing for Personalized Antiplatelet Therapy in 600-Patient Clinical Trial with Spartan Bioscience (PRWEB) March 18, 2014 Spartan Bioscience today announced the start of a 600-patient study of personalized medicine for cardiac stent patients in Germany. The study is part of a larger clinical trial entitled “Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes Trial (TROPICAL-ACS)”. TROPICAL-ACS, led by principal...

2014-03-03 16:25:40

SAN DIEGO and PARSIPPANY, N.J., March 3, 2014 /PRNewswire/ -- Shareholder rights law firm Robbins Arroyo LLP announces that an investor of The Medicines Company (NASDAQ: MDCO) has filed a federal securities fraud class action complaint in the U.S. District Court for the District of New Jersey. The complaint alleges that the company and certain of its officers and directors violated the Securities and Exchange Act of 1934 between February 20, 2013 and February 12, 2014 (the "Class...

2014-01-16 16:24:28

RARITAN, N.J., Jan. 16, 2014 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) announced today the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee has voted against the approval of the use of XARELTO(®) (rivaroxaban), an oral anticoagulant, to reduce the risk of thrombotic cardiovascular events in patients with Acute Coronary Syndrome (ACS) in combination with standard antiplatelet therapy. Janssen is seeking approval of...

2013-12-12 23:28:53

Rapid CYP2C19 Testing for Heart Attack Patients Using Antiplatelet Drugs in 150-Patient Clinical Trial With Spartan Bioscience Ottawa, Ontario (PRWEB) December 12, 2013 Spartan Bioscience today announced the start of a 150-patient study of personalized medicine for cardiac stent patients in Poland, Hungary, and Lithuania. The study is sponsored by the Medical University of Warsaw, and is entitled “Bedside Genetic or Pharmacodynamic Testing to Prevent Periprocedural Myonecrosis During...

2013-11-26 23:30:44

Spartan Bioscience announces 2,000-patient clinical trial of rapid DNA testing for heart attack patients using antiplatelet drugs. Ottawa, Ontario (PRWEB) November 26, 2013 Spartan Bioscience today announced the start of a 2,000-patient study of personalized medicine for cardiac stent patients in Saudi Arabia. The study is sponsored by the University of Dammam, and is entitled “Bedside Testing of CYP2C19 Gene for Treatment of Patients with PCI with Antiplatelet Therapy.” The Spartan...


Word of the Day
sough
  • A murmuring sound; a rushing or whistling sound, like that of the wind; a deep sigh.
  • A gentle breeze; a waft; a breath.
  • Any rumor that engages general attention.
  • A cant or whining mode of speaking, especially in preaching or praying; the chant or recitative characteristic of the old Presbyterians in Scotland.
  • To make a rushing, whistling, or sighing sound; emit a hollow murmur; murmur or sigh like the wind.
  • To breathe in or as in sleep.
  • To utter in a whining or monotonous tone.
According to the OED, from the 16th century, this word is 'almost exclusively Scots and northern dialect until adopted in general literary use in the 19th.'
Related